Regulatory & Legal

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A routine filing from a quant fund reveals subtle shifts in the high-stakes merger of American Axle and Dowlais. What does it mean for the bottom line?

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A key regulatory filing reveals growing investor confidence in the American Axle-Dowlais deal, a move poised to reshape the global automotive supply chain.

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.

Beyond straight teeth, a new aligner offers non-surgical jaw correction for adults, shaking up a multi-billion dollar market. Is this the future?

In a routine filing with major implications, Albion Crown VCT directors reinvest dividends, signaling deep faith in the VCT model as tax rules evolve.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

A monumental $31.5 billion contract tasks Peraton with replacing the FAA's aging air traffic control system. Can it succeed where others have failed?

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.

With $15M in new funding and seasoned mining execs on board, Getty Copper is now debt-free and poised to unlock the potential of its vast copper assets.

Promising Phase 3 data reveals a novel, organ-sparing laser therapy for a rare cancer, signaling a potential paradigm shift away from radical surgery.

Beyond the hype of air taxis, one Oregon firm is electrifying aviation's workhorses, from firefighting helicopters to military vehicles, in extreme conditions.

As REV Group preps its Q4 report, all eyes are on whether its booming specialty vehicle segment can offset volatility in the recreational vehicle market.

Westinghouse's new robotics deal with PROMATION is more than a partnership; it’s a key move in building a Canadian supply chain for a global nuclear revival.